Christy Oliger
About Christy Oliger
Independent director of Replimune Group (REPL), appointed December 1, 2021. Former Senior Vice President, Oncology Business Unit Head at Genentech (2000–2020). BA in Economics from the University of California, Santa Barbara. Age 55 as of 2025; tenure on REPL board ~4 years; independence affirmed by REPL and other boards.
Past Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Genentech, Inc. | Senior Vice President, Oncology Business Unit; prior SVP IMPACT BU; VP roles across portfolio planning/management and hematology marketing/sales | 2000–2020 | Led US commercial operations for oncology; broad therapeutic leadership (oncology, neurology, rare disease, respiratory, dermatology, immunology) |
| Schering‑Plough | Management positions | Pre‑2000 | Early commercial experience prior to Genentech |
External Roles
| Company | Role | Start | Committees/Position |
|---|---|---|---|
| Karyopharm Therapeutics (KPTI) | Director | Aug 2020 | Audit, Compensation, Nominating & Corporate Governance committees |
| LAVA Therapeutics (LVTX) | Director | Mar 2023 | Audit Committee member; independence affirmed |
| Vera Therapeutics (VERA) | Director | Jun 2024 | Nominating & Corporate Governance Committee member; independent |
| Nuvalent (NUVL) | Director (Class III) | Jun 18, 2025 | Audit Committee member; independent; initial equity grants on appointment |
Notable prior boards: Sierra Oncology (until acquisition by GSK in 2022), Reata Pharmaceuticals (until acquisition by Biogen in 2023), RayzeBio (until acquisition by BMS in 2024).
Board Governance
- Independence: REPL board determined Oliger is independent under SEC and Nasdaq rules.
- Committee history at REPL:
- 2021–2024: Audit Committee member (appointed Dec 1, 2021; replaced Kapil Dhingra; served until June 5, 2024).
- Since 2021: Research & Development (R&D) Committee member.
- Since Jun 5, 2024: Compensation Committee member; Chair as of FY2025.
- Current (FY2026 proxy): Compensation Committee Chair; R&D Committee member.
Fixed Compensation (REPL – initial appointment terms)
| Component | Annual Amount | Notes |
|---|---|---|
| Board cash retainer | $40,000 | Prorated from Dec 1, 2021; non‑employee director cash retainer |
| Audit Committee cash retainer | $7,500 | Prorated from Dec 1, 2021 |
| R&D Committee cash retainer | $6,000 | Prorated from Dec 1, 2021 |
Indemnification agreement and board appointment letter executed at appointment.
Performance Compensation (REPL)
| Award Type | Grant Date | Shares/Units | Exercise Price | Vesting |
|---|---|---|---|---|
| Nonqualified Stock Option | Dec 1, 2021 | 33,000 | $28.01 | 25% at first anniversary; remaining 75% in ~24 equal monthly installments thereafter |
No performance metrics, clawback provisions, or repricing disclosures specific to director awards were reported in REPL filings regarding Oliger’s grants.
Other Directorships & Interlocks
| Company | Sector Overlap with REPL | Potential Interlock/Note |
|---|---|---|
| KPTI (oncology) | High | Active committee roles; separate issuer governance affirmed independent status |
| LVTX (immuno‑oncology) | High | Audit Committee service; independent |
| VERA (immunology) | Moderate | Nominating Committee; independent |
| NUVL (oncology) | High | Audit Committee; initial director equity and cash retainers under NUVL policy |
No related‑party transactions disclosed by REPL at Oliger’s appointment; REPL reported none under Item 404(a).
Expertise & Qualifications
- Nearly 30 years of biopharma commercial leadership with emphasis on oncology; led Genentech’s US oncology commercial organization.
- Broad portfolio and R&D interface experience (portfolio management/planning; cross‑functional leadership).
- Active governance across multiple public biopharma boards, including audit, compensation, and nominating roles.
- BA in Economics (UC Santa Barbara).
Equity Ownership (REPL)
| As‑of Date | Beneficial Ownership (Shares) | Source |
|---|---|---|
| Jun 30, 2024 | 70,575 | REPL DEF 14A 2024 security ownership table |
| Jun 30, 2025 | 106,700 | REPL DEF 14A 2025 security ownership table |
Initial Form 3 (Dec 3, 2021) filed with “No securities are beneficially owned.” (reporting baseline at appointment).
Insider Filings (REPL)
| Filing | Date | Key Disclosure |
|---|---|---|
| Form 3 (Initial Statement of Beneficial Ownership) | Dec 3, 2021 | No securities beneficially owned at filing; power of attorney noted |
Governance Assessment
- Strengths:
- Independence across boards; REPL confirmed independence.
- Deep oncology commercial and portfolio expertise aligned with REPL’s strategy; provides value on R&D oversight and compensation matters.
- Meaningful ownership stake that increased from 2024 to 2025; alignment enhanced by vested options.
- Potential risks/considerations:
- Multiple concurrent biopharma directorships (KPTI, LVTX, VERA, NUVL) increase time‑commitment and create sector overlap; necessitates ongoing monitoring for conflicts (none disclosed to date at REPL).
- Committee rotation (leaving Audit in Jun 2024; assuming Compensation Chair) shifts governance responsibilities—effective oversight will hinge on continued engagement and attendance (no REPL‑specific attendance rates disclosed).
- Red flags observed: None disclosed regarding related‑party transactions, pledging/hedging, or option repricing in REPL filings relating to Oliger.
Board Governance (Committee Assignments – REPL)
| Period | Committee | Role |
|---|---|---|
| Dec 2021–Jun 2024 | Audit | Member (appointed Dec 1, 2021; replaced Dhingra) |
| Dec 2021–Present | Research & Development | Member |
| Jun 2024–Present | Compensation | Member; Chair as of FY2025 |
REPL governance framework includes Board oversight of ESG and risk via committees (Audit, Compensation, Nominating & Corporate Governance, R&D).
Fixed Compensation
| Category | Amount | Notes |
|---|---|---|
| Annual cash retainers (Board/Audit/R&D) | $40,000 / $7,500 / $6,000 | Initial appointment; prorated |
Performance Compensation
| Instrument | Fair Value Basis | Alignment Notes |
|---|---|---|
| Stock options (33,000 @ $28.01) | Fixed exercise price; time‑based vesting | Aligns with long‑term value creation; vesting schedule promotes sustained engagement |
Other Directorships & Interlocks
| Company | Role | Committee/Chair | Independence |
|---|---|---|---|
| KPTI | Director | Audit; Compensation; Nominating & Corporate Governance | Independent; committee independence affirmed |
| LVTX | Director | Audit | Independent |
| VERA | Director | Nominating & Corporate Governance | Independent |
| NUVL | Director | Audit | Independent; initial equity/cash retainers disclosed |
Transaction support agreements signed in LAVA acquisition context (XOMA tender offer) included Oliger as signatory among LAVA directors; typical for change‑of‑control processes.
Equity Ownership
| Year | Shares Owned | Notes |
|---|---|---|
| 2024 | 70,575 | From REPL 2024 proxy |
| 2025 | 106,700 | From REPL 2025 proxy |
Ownership tables may include options/RSUs exercisable/vesting within 60 days, per standard SEC beneficial ownership rules in proxy disclosures; REPL tables report aggregate beneficial ownership.
Governance Assessment (Summary)
- Overall: Strong governance profile with industry expertise, independence, and increasing equity alignment; committee leadership (Compensation Chair) and R&D oversight are positives for board effectiveness. Monitor sector overlap from multiple oncology‑adjacent boards; no REPL‑specific conflicts or related‑party exposures disclosed.